• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Public Health . Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections

tetano

Editor, Senior Moderator
J Infect Public Health


. 2021 Feb 20;14(5):655-660.
doi: 10.1016/j.jiph.2021.02.006. Online ahead of print.
Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections


S Saqrane[SUP] 1 [/SUP], M A El Mhammedi[SUP] 2 [/SUP], S Lahrich[SUP] 1 [/SUP], F Laghrib[SUP] 1 [/SUP], Y El Bouabi[SUP] 1 [/SUP], A Farahi[SUP] 1 [/SUP], M Bakasse[SUP] 1 [/SUP]



Affiliations

Abstract

The management of SARS-CoV-2 has not yet been clearly determined and is based on potential therapies evaluated during the SARS-CoV and MERS-CoV outbreaks. An emerging potential therapeutic approach currently being evaluated in numerous clinical trials is the remdesivir agent, which acts on COVID-19 by interfering with key steps in the virus replication cycle. It is considered a therapeutic option to be evaluated against COVID-19, based on data on its in vitro and in vivo activity against MERS-CoV and SARS-CoV coronaviruses. In this work, we provide an overview of remdesivir's discovery, mechanism of action, and the current studies exploring its clinical effectiveness. Recommendations for its use against COVID-19 infection are also summarized.

Keywords: COVID-19; Clinical tests; Remdesivir.
 
Back
Top Bottom